AROC is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy, but it is a reasonable hold. The stock has supportive fundamentals, a positive analyst trend, and bullish long-term moving averages, yet the latest quarter missed EPS expectations and insider selling has accelerated. Since the user wants a direct answer and is unwilling to wait for optimal entry, I would not call this a buy at the current price of 38.15; I would wait for a better entry rather than chase it now.
Technical trend is moderately positive. MACD histogram is above zero at 0.135, though it is contracting, which suggests upside momentum is still present but weakening. RSI_6 at 48.143 is neutral, so the stock is not overbought. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, supporting an upward medium- to long-term trend. Price is hovering near the pivot level of 38.136, with resistance at 39.763 and 40.769 and support at 36.509 and 35.503. This setup suggests the stock is trending upward but lacks a strong near-term breakout signal.

["Q1 2026 revenue rose 7.66% YoY to $373.8M", "Net income increased 6.27% YoY and gross margin improved slightly", "Adjusted EBITDA of $221M showed strong profitability", "Analyst targets have been raised repeatedly over the past few months, with multiple firms maintaining Buy/Outperform ratings", "Natural gas compression demand remains strong, supporting long-term growth", "Bullish option positioning suggests market participants expect upside"]
["Q1 2026 non-GAAP EPS of $0.42 missed estimates by $0.06", "The stock is trading near a pivot level with nearby resistance overhead, limiting immediate upside confidence", "Insiders have been selling, and selling activity increased 519.73% over the last month", "Hedge funds are neutral with no significant accumulation trend", "AI Stock Picker and SwingMax both show no signal today, so there is no proprietary strong-buy trigger"]
Latest quarter: Q1 2026. Revenue increased to $373.8M, up 7.66% year over year. Net income rose to $73.8M, up 6.27% YoY. EPS increased 5.00% YoY to $0.42, but it missed consensus by $0.06. Gross margin improved to 47.54%, up slightly year over year. Overall, the company showed healthy growth and solid profitability, but earnings came in below expectations.
Analyst sentiment is clearly positive and improving. Over the recent period, multiple firms raised price targets: Raymond James to $46 and Stifel to $41 on May 7, Mizuho to $38, RBC to $40, Evercore ISI to $42, Citi to $40, Wells Fargo to $39, and prior Stifel/Raymond James raises as well. The Wall Street pros view is constructive, with repeated Buy/Outperform/Overweight ratings and a higher target range, but the latest earnings miss and insider selling temper the enthusiasm somewhat.